| Members |
targetComponentId |
| Mental &/or developmental handicap screen |
Screening for developmental disorder (procedure) |
| Mental Health Act examination NOS |
Mental Health Act examination |
| Mental Health Act examination NOS |
Mental Health Act examination |
| Mental disorder - unspecified whether during pregnancy or the puerperium |
Mental disorders during pregnancy, childbirth and the puerperium |
| Mental disorder during pregnancy, childbirth or the puerperium NOS |
Mental disorders during pregnancy, childbirth and the puerperium |
| Mental disorders NOS |
Mental disorder |
| Mental disorders NOS |
Mental disorder |
| Mental disorders NOS |
Mental disorder |
| Mental disorders NOS |
Mental disorder |
| Mental handicap |
Intellectual disability |
| Mental handicap (specialty) |
Intellectual disability specialty |
| Mental handicap (specialty) |
Intellectual disability specialty |
| Mental handicap (specialty) |
Intellectual disability specialty |
| Mental handicap psychiatry department |
Intellectual disability psychiatry department (environment) |
| Mental handicap psychiatry service |
Intellectual disability psychiatry service |
| Mental health annual physical examination done |
Annual physical examination for people with mental illness completed |
| Mental health crisis plan |
Mental health crisis plan |
| Mental health personal health plan |
Mental health personal health plan |
| Mental retardation |
Intellectual disability |
| Mental retardation NOS |
Intellectual disability |
| Mental retardation NOS |
Intellectual disability |
| Mental retardation NOS |
Intellectual disability |
| Mental retardation screening |
Intellectual disability screening |
| Mental/developmental handicap screening |
Screening for developmental disorder (procedure) |
| Mental/developmental handicap screening NOS |
Screening for developmental disorder (procedure) |
| Mental/developmental handicap screening NOS |
Screening for developmental disorder (procedure) |
| Menthol 35.55mg inhalant capsule |
Product containing only menthol in pulmonary dose form (medicinal product form) |
| Mepacrine hydrochloride 100mg tablet |
Mepacrine hydrochloride 100 mg oral tablet |
| Meperidine hydrochloride 100mg/mL injection solution ampule |
Product containing only pethidine in parenteral dose form (medicinal product form) |
| Meperidine hydrochloride 50mg/5mL syrup |
Pethidine hydrochloride 10 mg/mL oral solution |
| Meperidine hydrochloride 50mg/mL injection solution ampule |
Product containing only pethidine in parenteral dose form (medicinal product form) |
| Meperidine hydrochloride 50mg/promethazine hydrochloride 50mg injection solution vial |
Product containing only pethidine and promethazine (medicinal product) |
| Mepivacaine hydrochloride 3%/levonordefrin 1:20,000 injection solution vial |
Corbadrine 50 microgram/mL and mepivacaine hydrochloride 30 mg/mL solution for injection |
| Mepivacaine hydrochloride 30mg/sodium chloride 3mg injection solution vial |
Mepivacaine only product |
| Mepivacaine hydrochloride+epinephrine 2%/1:100,000 cartridge |
Adrenaline 10 microgram/mL and mepivacaine hydrochloride 20 mg/mL solution for injection |
| Mepivacaine hydrochloride+epinephrine 2%/1:100,000 cartridge |
Adrenaline 10 microgram/mL and mepivacaine hydrochloride 20 mg/mL solution for injection |
| Meptazinol 100mg/1mL injection |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Meptazinol 100mg/mL injection solution 1mL ampule |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Meptazinol 200mg tablet |
Meptazinol (as meptazinol hydrochloride) 200 mg oral tablet |
| Mercurophylline injection |
Mercurophylline |
| Merselene patch |
Polyester mesh (physical object) |
| Mesalamine 250mg capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 250mg m/r capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 250mg prolonged-release oral capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 375mg m/r capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 375mg prolonged-release oral capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine 1g/100mL retention enema |
Mesalazine only product in rectal dose form |
| Mesalazine 1g/100mL retention enema |
Mesalazine only product in rectal dose form |
| Mesalazine 2g/59mL enema |
Mesalazine only product in rectal dose form |
| Mesalazine 500mg/sachet gastro-resistant and prolonged-release oral granules |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine 500mg/sachet m/r granules |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine duplicate deleted |
Product containing mesalazine (medicinal product) |
| Mesonephric tumor |
Wolffian tumor of uncertain behavior (morphologic abnormality) |
| Mesoridazine besylate 10mg/mL injection solution ampule |
Product containing precisely mesoridazine 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Mesoridazine besylate 25mg/mL injection solution ampule |
Product containing precisely mesoridazine 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Mesothelioma, biphasic, benign |
Mesothelioma, benign |
| Metabolic acidosis caused by ingestion of drugs AND/OR chemicals |
Metabolic acidosis |
| Metabolic disease, NEC |
Metabolic disease |
| Metabolic function test NOS |
Metabolic function test |
| Metabolic function test NOS |
Metabolic function test |
| Metabolic marker |
Inborn errors of metabolism marker |
| Metabolic monitoring NOS |
Metabolic monitoring procedure |
| Metabolic monitoring NOS |
Metabolic monitoring procedure |
| Metacarpal X-ray |
Plain X-ray of metacarpal bone |
| Metacarpal X-ray |
Plain X-ray of metacarpal bone |
| Metacarpal X-ray |
Plain X-ray of metacarpal bone |
| Metaiodobenzylguanidine[123I] 74MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[123I] 74MBq/mL powder for injection solution vial |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I] 37MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I] 37MBq/mL powder for injection solution vial |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I]370MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I]37MBq/mL diagnostic injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I]9.25MBq/mL diagnostic injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metal engineering machiner NOS |
Engineering machiner (occupation) |
| Metal engineering machiner NOS |
Engineering machiner (occupation) |
| Metal processor/treater NOS |
Metal processer |
| Metal processor/treater NOS |
Metal processer |
| Metal production fitter NOS |
Metal production fitter |
| Metal production fitter NOS |
Metal production fitter |
| Metal/electrical worker NOS |
Metal/electrical worker (occupation) |
| Metal/electrical worker NOS |
Metal/electrical worker (occupation) |
| Metallocarboxypeptidase |
Metallocarboxypeptidase |
| Metalloproteinase |
Metalloproteinase (substance) |
| Metaproterenol 20mg tablet |
Orciprenaline sulfate 20 mg oral tablet |
| Metaproterenol sulfate 0.65mg/inh aerosol |
Orciprenaline only product in pulmonary dose form |
| Metaproterenol sulfate 15mg/mL aerosol |
Product containing precisely orciprenaline sulfate 15 milligram/1 milliliter conventional release solution for inhalation (clinical drug) |
| Metastasis stage M1a |
American Joint Committee on Cancer cM1a (qualifier value) |
| Metastasis stage M1b |
American Joint Committee on Cancer cM1b (qualifier value) |
| Metastasis stage M1c |
American Joint Committee on Cancer cM1c (qualifier value) |
| Metastasis stage M2 |
American Joint Committee on Cancer cM1 (qualifier value) |
| Metastasis stage M3 |
American Joint Committee on Cancer cM1 (qualifier value) |
| Metastasis stage M4 |
American Joint Committee on Cancer cM1 (qualifier value) |
| Metastasis stage pM1 |
American Joint Committee on Cancer pM1 (qualifier value) |
| Metastasizing pleomorphic adenoma |
Pleomorphic adenoma |
| Metastatic apocrine adenocarcinoma to skin |
Metastatic apocrine adenocarcinoma (disorder) |
| Metastatic carcinoid tumor |
Metastatic well-differentiated neuroendocrine tumor (disorder) |
| Metastatic carcinoid tumor |
Metastatic well-differentiated neuroendocrine tumor (morphologic abnormality) |
| Metastatic carcinoma to female breast |
Metastatic carcinoma to breast |
| Metastatic carcinoma to male breast |
Metastatic carcinoma to breast |
| Metastatic cholangiocarcinoma to biliary tract |
Metastatic cholangiocarcinoma (morphologic abnormality) |
| Metastatic cholangiocarcinoma to perihilar bile duct |
Metastatic cholangiocarcinoma |